Integra LifeSciences (NASDAQ:IART – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to announce earnings of $0.5630 per share and revenue of $413.16 million for the quarter. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:30 AM ET.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. On average, analysts expect Integra LifeSciences to post $2.39 EPS for the current fiscal year and $2.47 EPS for the next fiscal year.
Integra LifeSciences Price Performance
NASDAQ IART opened at $13.21 on Monday. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The company has a market cap of $1.03 billion, a PE ratio of -146.76, a price-to-earnings-growth ratio of 0.70 and a beta of 1.21. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The firm’s 50-day simple moving average is $15.82 and its two-hundred day simple moving average is $15.49.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on IART. BMO Capital Markets lowered their price target on shares of Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating on the stock in a research report on Monday, October 5th. Wells Fargo & Company set a $15.00 price target on shares of Integra LifeSciences in a research note on Saturday, October 3rd. Citigroup reaffirmed a “neutral” rating and issued a $15.00 price objective (down from $19.00) on shares of Integra LifeSciences in a report on Monday, October 5th. UBS Group started coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective for the company. Finally, Weiss Ratings lowered shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $16.71.
Read Our Latest Stock Report on Integra LifeSciences
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.
The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.
Read More
- Five stocks we like better than Integra LifeSciences
- These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
- Meta Claims Frontier-Class AI Status With New Muse Wonder Models
- Berkshire Just Backed This Little-Known Stock—Should You Chase It?
- Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
